Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
出版年份 2023 全文链接
标题
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
作者
关键词
-
出版物
NATURE MEDICINE
Volume 29, Issue 9, Pages 2259-2267
出版商
Springer Science and Business Media LLC
发表日期
2023-08-16
DOI
10.1038/s41591-023-02528-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
- (2023) Niels W.C.J. van de Donk et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
- (2023) Heinz Ludwig et al. LANCET ONCOLOGY
- Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
- (2023) Evangelos Terpos et al. LEUKEMIA
- Infectious complications of bispecific antibody therapy in patients with multiple myeloma
- (2023) Beatrice Z. Sim et al. Blood Cancer Journal
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- (2023) Farah Mazahreh et al. Blood Advances
- Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
- (2023) Noopur Raje et al. Blood Cancer Journal
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
- (2022) Noopur S Raje et al. Lancet Haematology
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- (2022) Maria-Victoria Mateos et al. LEUKEMIA
- Extramedullary disease in multiple myeloma: a systematic literature review
- (2022) Joan Bladé et al. Blood Cancer Journal
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
- (2022) Thomas Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
- (2022) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
- (2022) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- (2022) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
- (2022) Sarvarinder K. Gill et al. Blood Cancer Journal
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
- (2022) Noopur Raje et al. BLOOD
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
- (2022) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular therapy for multiple myeloma: what's now and what's next
- (2022) Paula Rodriguez-Otero et al. Hematology-American Society of Hematology Education Program
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy
- (2021) Swetha Kambhampati et al. Blood Advances
- Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Alexander Lesokhin et al. BLOOD
- Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
- (2021) Lekha Mikkilineni et al. Blood Advances
- Risk of infections with B cell maturation antigen (BCMA) directed Immunotherapy in Multiple Myeloma
- (2021) Meera Mohan et al. Blood Advances
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
- (2019) Siler H. Panowski et al. MOLECULAR CANCER THERAPEUTICS
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started